Stelara (Ustekinumab) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The stelara (ustekinumab) market size has grown strongly in recent years. It will grow from $11.85 million in 2025 to $12.54 million in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to limitations of conventional immunosuppressants, rising prevalence of autoimmune diseases, strong clinical efficacy data, hospital-based biologic administration, demand for durable remission.

The stelara (ustekinumab) market size is expected to see strong growth in the next few years. It will grow to $15.57 million in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to growth in inflammatory bowel disease cases, expansion of biologic reimbursement coverage, patient preference for less frequent dosing, biosimilar competition impact, improved biologic delivery devices. Major trends in the forecast period include rising use of targeted biologic therapies, expansion of autoimmune disease indications, shift toward long-term maintenance treatment, growing adoption of subcutaneous biologics, increase in home-based administration.

The increasing prevalence of psoriasis patients is expected to drive the growth of the Stelara (ustekinumab) market in the coming years. Psoriasis is a chronic autoimmune disorder that accelerates skin cell turnover, resulting in red, scaly patches. The rising prevalence of psoriasis is influenced by factors such as improved diagnosis, environmental triggers, genetic predisposition, and an aging population. Stelara (ustekinumab) works by targeting and inhibiting interleukin-12 and interleukin-23, helping psoriasis patients by reducing inflammation and plaque formation, improving skin clearance, and supporting long-term symptom management, ultimately enhancing quality of life. For example, in August 2024, the National Psoriasis Foundation (NPF), a US-based non-profit organization, reported that psoriasis affects approximately 3% of U.S. adults aged 20 and above, representing over 7 million individuals. Additionally, around 600,000 adults in the U.S. are believed to have psoriasis but remain undiagnosed. Consequently, the rising prevalence of psoriasis patients is expected to propel the growth of the Stelara (ustekinumab) market.

Key companies in the Stelara (ustekinumab) market are developing innovative products, including biosimilars, to offer cost-effective treatment options for patients with chronic inflammatory conditions. Stelara biosimilars are biologically similar medications designed to replicate the therapeutic effects of Stelara (ustekinumab), targeting IL-12 and IL-23 to treat autoimmune conditions such as psoriasis and psoriatic arthritis. For instance, in October 2024, Accord BioPharma Inc., a US-based biopharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for IMULDOSA (ustekinumab-srlf), a biosimilar to Johnson & Johnson’s STELARA (ustekinumab). IMULDOSA offers broad indications, treating adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, and ulcerative colitis. It is also approved for pediatric patients aged 6 years and older with moderate to severe plaque psoriasis and active psoriatic arthritis, making it a versatile option across age groups. This extensive coverage positions IMULDOSA as a valuable choice for managing various immune-mediated inflammatory diseases.

In December 2023, Lotus Pharmaceutical, a Taiwan-based company, partnered with Favorex Pte Ltd., a Singapore-based pharmaceutical firm, to introduce a biosimilar of ustekinumab to the South Korean market. Through this partnership, Lotus Pharmaceutical aims to leverage Favorex’s expertise and market presence to meet the demand for cost-effective biologic therapies and expand its footprint in the region’s pharmaceutical sector.

Major companies operating in the stelara (ustekinumab) market are Johnson & Johnson.

North America was the largest region in the stelara (ustekinumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stelara (ustekinumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the stelara (ustekinumab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the stelara market by increasing costs for monoclonal antibody production inputs, sterile packaging, and temperature-controlled transportation. These cost pressures have affected hospital pharmacy and specialty clinic procurement, especially in regions relying on imported biologics. Asia-pacific and middle east markets face higher pricing sensitivity due to cross-border sourcing. On the positive side, tariffs have encouraged regional biologics manufacturing, strengthened local supply chains, and supported long-term treatment access for autoimmune patients.

The stelara (ustekinumab) market research report is one of a series of new reports that provides stelara (ustekinumab) market statistics, including stelara (ustekinumab) industry global market size, regional shares, competitors with a stelara (ustekinumab) market share, detailed stelara (ustekinumab) market segments, market trends and opportunities, and any further data you may need to thrive in the stelara (ustekinumab) industry. This stelara (ustekinumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Stelara (Ustekinumab) is a monoclonal antibody that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), key proteins involved in inflammatory and autoimmune processes. It is commonly used to treat moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.

The main indications for Stelara (Ustekinumab) include plaque psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, and other related conditions. Plaque psoriasis is a chronic autoimmune disorder marked by rapid skin cell buildup, resulting in scaly, inflamed patches, often affecting the scalp, elbows, and knees. Stelara can be administered via subcutaneous injection or intravenous infusion and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies. It is indicated for pediatric, adult, and geriatric patients.

The stelara (ustekinumab) market consists of sales of small-molecule drugs, vaccines, immunotherapy products, biosimilars and injectable drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.